SYNEOS HEALTH INC (SYNH) Fundamental Analysis & Valuation

NASDAQ:SYNH • US87166B1026

42.98 USD
+0.01 (+0.02%)
At close: Sep 27, 2023
42.97 USD
-0.01 (-0.02%)
After Hours: 9/27/2023, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SYNH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

SYNH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. There are concerns on the financial health of SYNH while its profitability can be described as average. SYNH may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

4

1. SYNH Profitability Analysis

1.1 Basic Checks

  • In the past year SYNH was profitable.
  • SYNH had a positive operating cash flow in the past year.
SYNH Yearly Net Income VS EBIT VS OCF VS FCFSYNH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M 400M

1.2 Ratios

  • With a decent Return On Assets value of 0.88%, SYNH is doing good in the industry, outperforming 70.31% of the companies in the same industry.
  • SYNH has a better Return On Equity (2.04%) than 71.88% of its industry peers.
  • SYNH has a Return On Invested Capital of 4.23%. This is in the better half of the industry: SYNH outperforms 70.31% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for SYNH is significantly below the industry average of 11.61%.
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROIC 4.23%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
SYNH Yearly ROA, ROE, ROICSYNH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 10 20 30

1.3 Margins

  • SYNH's Profit Margin of 1.31% is fine compared to the rest of the industry. SYNH outperforms 70.31% of its industry peers.
  • SYNH's Profit Margin has improved in the last couple of years.
  • SYNH has a better Operating Margin (6.33%) than 65.63% of its industry peers.
  • SYNH's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 22.14%, SYNH is doing worse than 84.38% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SYNH has remained more or less at the same level.
Industry RankSector Rank
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
SYNH Yearly Profit, Operating, Gross MarginsSYNH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SYNH Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SYNH is destroying value.
  • SYNH has less shares outstanding than it did 1 year ago.
  • The debt/assets ratio for SYNH has been reduced compared to a year ago.
SYNH Yearly Shares OutstandingSYNH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
SYNH Yearly Total Debt VS Total AssetsSYNH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

  • Based on the Altman-Z score of 1.46, we must say that SYNH is in the distress zone and has some risk of bankruptcy.
  • SYNH has a Altman-Z score (1.46) which is comparable to the rest of the industry.
  • SYNH has a debt to FCF ratio of 16.71. This is a negative value and a sign of low solvency as SYNH would need 16.71 years to pay back of all of its debts.
  • SYNH has a better Debt to FCF ratio (16.71) than 65.63% of its industry peers.
  • SYNH has a Debt/Equity ratio of 0.77. This is a neutral value indicating SYNH is somewhat dependend on debt financing.
  • SYNH has a worse Debt to Equity ratio (0.77) than 79.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Altman-Z 1.46
ROIC/WACC0.39
WACC10.92%
SYNH Yearly LT Debt VS Equity VS FCFSYNH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

2.3 Liquidity

  • SYNH has a Current Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.20, SYNH is doing worse than 93.75% of the companies in the same industry.
  • A Quick Ratio of 1.20 indicates that SYNH should not have too much problems paying its short term obligations.
  • SYNH has a worse Quick ratio (1.20) than 82.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.2
SYNH Yearly Current Assets VS Current LiabilitesSYNH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SYNH Growth Analysis

3.1 Past

  • The earnings per share for SYNH have decreased strongly by -23.79% in the last year.
  • Measured over the past years, SYNH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.74% on average per year.
  • SYNH shows a small growth in Revenue. In the last year, the Revenue has grown by 0.01%.
  • Measured over the past years, SYNH shows a quite strong growth in Revenue. The Revenue has been growing by 15.08% on average per year.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%

3.2 Future

  • Based on estimates for the next years, SYNH will show a small growth in Earnings Per Share. The EPS will grow by 3.17% on average per year.
  • SYNH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.71% yearly.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SYNH Yearly Revenue VS EstimatesSYNH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
SYNH Yearly EPS VS EstimatesSYNH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. SYNH Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 11.37, the valuation of SYNH can be described as reasonable.
  • 100.00% of the companies in the same industry are more expensive than SYNH, based on the Price/Earnings ratio.
  • SYNH is valuated cheaply when we compare the Price/Earnings ratio to 26.69, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 10.48, the valuation of SYNH can be described as very reasonable.
  • SYNH's Price/Forward Earnings ratio is rather cheap when compared to the industry. SYNH is cheaper than 100.00% of the companies in the same industry.
  • SYNH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.79.
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
SYNH Price Earnings VS Forward Price EarningsSYNH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • SYNH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SYNH is cheaper than 95.31% of the companies in the same industry.
  • 85.94% of the companies in the same industry are more expensive than SYNH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 27.53
EV/EBITDA 12.05
SYNH Per share dataSYNH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SYNH Dividend Analysis

5.1 Amount

  • SYNH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SYNH Fundamentals: All Metrics, Ratios and Statistics

SYNEOS HEALTH INC

NASDAQ:SYNH (9/27/2023, 8:00:01 PM)

After market: 42.97 -0.01 (-0.02%)

42.98

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-09
Earnings (Next)11-02
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Revenue(TTM)5.42B
Net Income(TTM)71.22M
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
P/S 0.82
P/FCF 27.53
P/OCF 17.62
P/B 1.28
P/tB N/A
EV/EBITDA 12.05
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROCE 5.32%
ROIC 4.23%
ROICexc 4.29%
ROICexgc 32.26%
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
FCFM 2.99%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexgc growth 3Y-8.19%
ROICexgc growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Debt/EBITDA 4.56
Cap/Depr 37.2%
Cap/Sales 1.68%
Interest Coverage 250
Cash Conversion 43.05%
Profit Quality 227.34%
Current Ratio 1.2
Quick Ratio 1.2
Altman-Z 1.46
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%

SYNEOS HEALTH INC / SYNH FAQ

What is the ChartMill fundamental rating of SYNEOS HEALTH INC (SYNH) stock?

ChartMill assigns a fundamental rating of 5 / 10 to SYNH.


What is the valuation status of SYNEOS HEALTH INC (SYNH) stock?

ChartMill assigns a valuation rating of 7 / 10 to SYNEOS HEALTH INC (SYNH). This can be considered as Undervalued.


Can you provide the profitability details for SYNEOS HEALTH INC?

SYNEOS HEALTH INC (SYNH) has a profitability rating of 6 / 10.


What is the financial health of SYNEOS HEALTH INC (SYNH) stock?

The financial health rating of SYNEOS HEALTH INC (SYNH) is 4 / 10.


Can you provide the expected EPS growth for SYNH stock?

The Earnings per Share (EPS) of SYNEOS HEALTH INC (SYNH) is expected to decline by -25.43% in the next year.